Overall market sentiment has been neutral on Ibio Inc (IBIO) stock lately. IBIO receives a Neutral rating from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company.
Recent trends are a good indator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive.
InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend.
Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .
What's Happening With IBIO Stock Today?
Ibio Inc (IBIO) stock is down -8.11% while the S&P 500 is up 0.48% as of 3:14 PM on Wednesday, Jul 1. IBIO is lower by -$0.18 from the previous closing price of $2.22 on volume of 17,803,624 shares. Over the past year the S&P 500 is higher by 5.09% while IBIO is up 191.43%. IBIO lost -$1.18 per share in the over the last 12 months.
To screen for more stocks like Ibio Inc click here.
More About Ibio Inc
iBio Inc is a part of the healthcare sector. Its main business is commercialized technologies and product candidates and manufacturing services to clients and collaborators. Its main area of business is plant-based protein expression technologies for vaccines and therapeutic proteins and developing and commercializing select biopharmaceutical product candidates. Its products are used to combat various areas such as fibrotic diseases, vaccines, enzyme replacements, monoclonal antibodies, and recombinant versions of marketed products.
